DPI reformed the report card scoring system in 2025 and eliminated the ability to compare overall scores and “achievement” ...

Virtus Newfleet Multi-Sector Bond ETF beat its benchmark in late 2025 as confidence grew. Review these strategic credit ...

Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant ...

On the night Avery Gamble was recognized for being the 11th girls' basketball player at Oliver Ames to record 1,000 points, ...

Alpelisib plus fulvestrant significantly improved PFS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer, achieving a median PFS of 7.4 months versus 2.8 months with placebo. The ...

The US municipal bond market recorded a 3.00% return in 3Q25 as monetary easing and strong demand offset heavy issuance.

The Huskies were 9-4 and stomped Boise State in the LA Bowl, a solid second season under Jedd Fisch by most measures.

Patients with treatment-naïve chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who received pirtobrutinib (Jaypirca; Eli Lilly) monotherapy showed an 80% reduction in progression ...

Who's in the hunt to go No. 1? How does the QB class look? Which teams need defense? And who could rise at the combine? Let's ...

A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...

Elacestrant combined with everolimus or abemaciclib showed significant PFS benefits in ER-positive, HER2-negative metastatic breast cancer patients. The ELEVATE trial reported median PFS of 8.3 months ...

It’s official: “Six Seven” Just earned the title of Dictionary.com’s 2025 Word of the Year. But even as the word is officially added to the cultural lexicon, it has already been quietly removed ...